Her2-positive breast cancer Trials in Seattle, United States
Conditions / Her2-positive breast cancer / Seattle, United States
Research into Her2-positive breast cancer spans multiple therapeutic approaches and trial phases.
26 total trials for this combination
Showing top 10 of 26 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT02614794 | A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer | COMPLETED | PHASE2 |
| NCT04660929 | CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors | ACTIVE_NOT_RECRUITING | PHASE1 |
| NCT03975647 | A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT05721248 | STOP-HER2: Stopping Trastuzumab in HER2+ MBC | ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT04425018 | MARGetuximab Or Trastuzumab (MARGOT) | ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT05705401 | Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer | ACTIVE_NOT_RECRUITING | — |
| NCT03530696 | T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer | COMPLETED | PHASE2 |
| NCT04585750 | The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) | RECRUITING | PHASE1/PHASE2 |
| NCT05705401 | Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer | ACTIVE_NOT_RECRUITING | — |
| NCT01042379 | I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer | RECRUITING | PHASE2 |